Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18640051 | 0.88 | MAPT (0.55) | LGMNMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL21533588 | 0.87 | LGMN (0.69) | LGMNMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL13722551 | 0.85 | LGMN (0.61) | LGMNMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3221137 | 0.85 | LGMN (0.61) | LGMNMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL30479029 | 0.85 | LGMN (0.61) | LGMNMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL25031058 | 0.85 | LGMN (0.61) | LGMNMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL21533589 | 0.82 | LGMN (0.66) | LGMNMAPTALDH1A1KDM4EMAPK1 | |
| SCHEMBL3139067 | 0.82 | MAPT (0.67) | LGMNMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL23086805 | 0.81 | LGMN (0.62) | LGMNMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL13896504 | 0.81 | ALDH1A1 (0.69) | LGMNMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377717-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180251429-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2018-09-06 | — | — | US | disclosed |
| EP-3350166-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017049177-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251429-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | LGMN 3458/4885MAPT 4394/4885ALDH1A1 2205/4885 |
| US-10377717-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | LGMN 3458/4885MAPT 4394/4885ALDH1A1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.